Thiazolidinediones (TZDs), a class of antihyperglycemic drugs able to activate PPAR-γ, that include rosiglitazone and pioglitazone (Lehmann et al., 1995) have been proposed as potential drugs to target fibrosis in EoE, also for the ability to act mainly at the level of damaged tissue, sparing healthy areas. The gene discussed is PPARG; the disease is eosinophilic esophagitis.